If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.



Business Roundup

September 14, 2009 | A version of this story appeared in Volume 87, Issue 37

The Society of Chemical Manufacturers & Affiliates’ president and CEO, Joseph Acker, will retire in December. Acker has led the trade association for more than six years. SOCMA has begun searching for a replacement.

Dow Chemical will close styrene and ethylbenzene plants at its Freeport, Texas, site by the end of the year. The firm closed a smaller styrene plant at the site late last year.

Dow Chemical has signed an agreement to sell its hollow-sphere plastic pigment line to Omnova Solutions for an undisclosed sum. The Federal Trade Commission required Dow to sell the business as a condition of approving its acquisition of Rohm and Haas.

Bayer CropScience has invested more than $7 million to expand its chemical-compound storage facility in Monheim, Germany. Bayer says the collection contains about 2.2 million substances used in the search for promising crop protection active ingredients.

Xoma and Arana Therapeutics, a subsidiary of Cephalon, will collaborate on antibody-based drug development using Xoma technologies. Arana will spend $6 million up front and will pay other fees to access Xoma’s antibody discovery, engineering, and manufacturing capabilities, along with its antibody phage-display libraries.

BioLeap will use its computational fragment-based drug design technology to create novel compounds for Glaxo­SmithKline drug targets. The targets are ones for which high-throughput screening and other methods have failed to generate any leads. GSK will synthesize the compounds and test them.

Sigma Pharmaceuticals will acquire a Bristol-Myers Squibb plant in Australia for $51 million. The Australian firm will supply products to BMS for up to five years. Sigma also gets the right to sell 15 branded drugs in Australia and New Zealand.


This article has been sent to the following recipient:

Chemistry matters. Join us to get the news you need.